14

	Application No.	Applicant(s)
Notice of Allowability	10/649,138	GAETA ET AL.
	Examiner	Art Unit
	lon D. Foneroen	1630
•	Jon D. Epperson	1639
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to 11 April 2007.		
2. The allowed claim(s) is/are 2-20 (renumbered 1-19).		
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) All b) Some* c) None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet: Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☑ Notice of References Cited (PTO-892)	5. ☐ Notice of Inform	nal Patent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summ	
3. Information Disclosure Statements (PTO/SB/08),	Paper No./Mail 7.	
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛭 Examiner's Stat	ement of Reasons for Allowance
or blological material	9. 🔲 Other	
	•	
·		

Application/Control Number: 10/649,138 Page 2

Art Unit: 1639

DETAILED ACTION

Status of the Application

1. Receipt is acknowledged of a response to a non-final office action, which was dated on April 11, 2007.

Status of the Claims

2. Claim 2-20 are pending and examined on the merits.

Withdrawn rejections

3. All previous rejections and/or objections are withdrawn in view of Applicants' arguments and/or terminal disclaimer. Specifically, the Examiner finds support under 35 U.S.C. § 112, first paragraph for the disputed claim language (i.e., any of A1 to M1 is a D-amino acid) at the indicated passages and in further view of Applicants' arguments corresponding thereto (e.g., 4/11/07 Response, page 5, last two paragraphs wherein original claim 1 and page 10 were cited). In addition, Applicants' arguments with regard to two of the double patenting rejections were found persuasive for the reasons set forth therein (e.g., see 4/11/07 Response, page 6, paragraphs 2 and 3). Finally, Applicants' submission of a terminal disclaimer for the '600 patent overcomes this rejection as well.

Reasons for Allowance

4. The prior art of record does not teach or fairly suggest Applicants' claimed agonists and methods of use. For example, Sanke et al. disclose a structurally related λhIAP-1 sequence (e.g., see Sanke et al., "An Islet Mayloid Peptide is derived from an 89-amino acid precursor by proteolytic processing" *J. Biol. Chem.* **1988**, *263(33)*, 17243-17246, especially page 17244,

Application/Control Number: 10/649,138

Art Unit: 1639

figure 2a), but this sequence was explicitly excluded from the scope of Applicants' claims (e.g., see proviso language in claim 12, section (a) corresponding to SEQ ID 45). Therefore, claims 2-20 renumbered 1-19 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Salutation

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jon D Epperson whose telephone number is (571) 272-0808. The examiner can normally be reached Monday-Friday from 9:00 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James (Doug) Schultz can be reached on (571) 272-0763. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jon D. Epperson, Ph.D. April 26, 2007

JON EPPERSON PRIMARY EXAMINER Page 3